1. Known or suspected symptomatic viral infection within 14 days of dosing initiation. 2. Signs of active pulmonary infection or pulmonary inflammatory conditions within 14 days of dosing. 3. History of hypersensitivity or allergies to a biologic drug or a constituent of the study drug or placebo. 4. History of previous administration of a monoclonal antibody or any inhaled biologic. 5. History of vaccination against SARS-CoV-2. 6. History of atopy or airway hyperresponsiveness.

1. Known or suspected symptomatic viral infection within 14 days of dosing initiation. 2. Signs of active pulmonary infection or pulmonary inflammatory conditions within 14 days of dosing. 3. History of hypersensitivity or allergies to a biologic drug or a constituent of the study drug or placebo. 4. History of previous administration of a monoclonal antibody or any inhaled biologic. 5. History of vaccination against SARS-CoV-2. 6. History of atopy or airway hyperresponsiveness.